Skip to main content

Market Overview

Why Gracell Biotechnologies Stock Is Trading Higher Today


Gracell Biotechnologies (NASDAQ: GRCL) shares are trading higher Wednesday after Citigroup initiated coverage on the stock with a Buy rating and a price target of $35 per share.

Gracell Biotechnologies is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer.

Gracell Biotechnologies’s stock was up 7.63% at $27.94. The stock has a 52-week high of $28.88 and a 52-week low of $20.12.


Related Articles (GRCL)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at